176 related articles for article (PubMed ID: 22415063)
1. Multidimensional plasma protein separation technique for identification of potential Alzheimer's disease plasma biomarkers: a pilot study.
Henkel AW; Müller K; Lewczuk P; Müller T; Marcus K; Kornhuber J; Wiltfang J
J Neural Transm (Vienna); 2012 Jul; 119(7):779-88. PubMed ID: 22415063
[TBL] [Abstract][Full Text] [Related]
2. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.
Bibl M; Mollenhauer B; Esselmann H; Lewczuk P; Klafki HW; Sparbier K; Smirnov A; Cepek L; Trenkwalder C; Rüther E; Kornhuber J; Otto M; Wiltfang J
Brain; 2006 May; 129(Pt 5):1177-87. PubMed ID: 16600985
[TBL] [Abstract][Full Text] [Related]
3. Multiplex immunoassay measurement of amyloid-β
Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
[TBL] [Abstract][Full Text] [Related]
4. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
5. Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer's disease.
Kitamura Y; Usami R; Ichihara S; Kida H; Satoh M; Tomimoto H; Murata M; Oikawa S
Neurol Res; 2017 Mar; 39(3):231-238. PubMed ID: 28107809
[TBL] [Abstract][Full Text] [Related]
6. Laboratory biomarkers in Alzheimer's disease.
Steinerman JR; Honig LS
Curr Neurol Neurosci Rep; 2007 Sep; 7(5):381-7. PubMed ID: 17764627
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer's disease - A cross-validation study.
Chiu MJ; Chen TF; Hu CJ; Yan SH; Sun Y; Liu BH; Chang YT; Yang CC; Yang SY
Nanomedicine; 2020 Aug; 28():102182. PubMed ID: 32222476
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E4 serum concentration for increased sensitivity and specificity of diagnosis of drug treated Alzheimer's disease patients vs. drug treated parkinson's disease patients vs. age-matched normal controls.
Goldknopf IL; Park HR; Sabbagh M
Curr Alzheimer Res; 2012 Dec; 9(10):1149-67. PubMed ID: 22950864
[TBL] [Abstract][Full Text] [Related]
9. Proteome-based plasma biomarkers for Alzheimer's disease.
Hye A; Lynham S; Thambisetty M; Causevic M; Campbell J; Byers HL; Hooper C; Rijsdijk F; Tabrizi SJ; Banner S; Shaw CE; Foy C; Poppe M; Archer N; Hamilton G; Powell J; Brown RG; Sham P; Ward M; Lovestone S
Brain; 2006 Nov; 129(Pt 11):3042-50. PubMed ID: 17071923
[TBL] [Abstract][Full Text] [Related]
10. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease.
Whelan CD; Mattsson N; Nagle MW; Vijayaraghavan S; Hyde C; Janelidze S; Stomrud E; Lee J; Fitz L; Samad TA; Ramaswamy G; Margolin RA; Malarstig A; Hansson O
Acta Neuropathol Commun; 2019 Nov; 7(1):169. PubMed ID: 31694701
[TBL] [Abstract][Full Text] [Related]
11. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
12. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
13. Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.
Jahn H; Wittke S; Zürbig P; Raedler TJ; Arlt S; Kellmann M; Mullen W; Eichenlaub M; Mischak H; Wiedemann K
PLoS One; 2011; 6(10):e26540. PubMed ID: 22046305
[TBL] [Abstract][Full Text] [Related]
14. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
Engelborghs S
Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
[TBL] [Abstract][Full Text] [Related]
15. Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer's disease patients from non-demented subjects.
Nagaraj S; Laskowska-Kaszub K; Dębski KJ; Wojsiat J; Dąbrowski M; Gabryelewicz T; Kuźnicki J; Wojda U
Oncotarget; 2017 Mar; 8(10):16122-16143. PubMed ID: 28179587
[TBL] [Abstract][Full Text] [Related]
16. Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia.
Alexopoulos P; Thierjung N; Economou P; Werle L; Buhl F; Kagerbauer S; Papanastasiou AD; Grimmer T; Gourzis P; Berthele A; Hemmer B; Kübler H; Martin J; Politis A; Perneczky R
J Alzheimers Dis; 2019; 69(1):83-90. PubMed ID: 30909232
[TBL] [Abstract][Full Text] [Related]
17. Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias.
Genius J; Klafki H; Benninghoff J; Esselmann H; Wiltfang J
Eur Arch Psychiatry Clin Neurosci; 2012 Nov; 262 Suppl 2():S71-7. PubMed ID: 22986448
[TBL] [Abstract][Full Text] [Related]
18. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
[TBL] [Abstract][Full Text] [Related]
19. SpotLight Proteomics: uncovering the hidden blood proteome improves diagnostic power of proteomics.
Lundström SL; Zhang B; Rutishauser D; Aarsland D; Zubarev RA
Sci Rep; 2017 Feb; 7():41929. PubMed ID: 28167817
[TBL] [Abstract][Full Text] [Related]
20. Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study.
Costa AC; Joaquim HPG; Forlenza OV; Gattaz WF; Talib LL
Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):483-488. PubMed ID: 31218445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
